Roger M. Perlmutter

Dr. Perlmutter is an Executive Vice President of Merck & Co and the President of Merck Research Laboratories. In this role, he directs the efforts of more than 13,000 scientists, physicians and engineers who are engaged in translating breakthrough biomedical research into medicines that improve the lives of people around the world.  Recently approved drugs include pembrolizumab, which is used to treat advanced malignancy, especially metastatic melanoma and non-small-cell lung cancer, and grazoprevir/elbasvir, a direct-acting agent for the elimination of hepatitis C virus infection.  In addition to directing biomedical research, Dr. Perlmutter serves as chair of the Board of Trustees of Reed College (Portland,OR), and is a board member of the Institute for Systems Biology in Seattle, Washington.